(Q35637066)

English

Daptomycin

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

Daptomycin (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Kerry L Tedesco

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Michael J Rybak

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

41-57

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Antimicrobial resistance in intensive care units

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Antimicrobial resistance of Staphylococcus aureus isolated from skin infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Bacterial meningitis in the United States in 1995. Active Surveillance Team

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Development of daptomycin for gram-positive infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro bactericidal activity of daptomycin against staphylococci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

The in-vitro activity of RP 59500 against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Once-daily dosing in dogs optimizes daptomycin safety

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Effect of protein binding of daptomycin on MIC and antibacterial activity

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Bactericidal activity of daptomycin against vancomycin-resistantEnterococcus faecium in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Resistance studies with daptomycin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Daptomycin (LY146032) treatment of experimental enterococcal endocarditis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.41.34802

21 January 2018

Identifiers

10.1592/PHCO.24.1.41.34802

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35637066&oldid=1582159570"